At a glance
| Approved product | Prialt |
|---|---|
| Main target | N-type calcium channels |
| Route context | Specialist intrathecal infusion |
| Clinical role | Severe chronic refractory or treatment-intolerant pain |
| Key warning | Severe psychiatric and neurologic reactions |
Overview
Ziconotide reproduces a peptide originally identified in cone-snail venom, but the medicine is manufactured synthetically. It is used when intrathecal therapy is appropriate and pain remains refractory to, or other treatment is poorly tolerated. The approved product requires a specialist delivery system and careful clinical management. Its non-opioid mechanism is scientifically distinctive, yet that distinction does not make treatment low risk. The evidence pertains to severe pain in defined clinical settings. It provides no basis for using ziconotide as a cognitive enhancer, an oral supplement, or a routine treatment for minor pain.
How it works
Ziconotide inhibits presynaptic N-type voltage-sensitive calcium channels in spinal pain pathways. Less calcium enters the nerve terminal, reducing release of neurotransmitters involved in pain transmission. Its action does not depend on opioid receptors. Delivery directly into cerebrospinal fluid is integral to the approved therapy; changing the route changes exposure and cannot be inferred to preserve either the benefit or the safety profile.
Clinical evidence
A randomized trial enrolled 111 people with cancer or AIDS and refractory pain. Pain-intensity scores improved more with intrathecal ziconotide than placebo during the short initial treatment period. The study demonstrates analgesic activity in a difficult clinical population, but its short duration and selected participants should not be generalized to every pain condition.
Supporting sources [2]
Why specialist monitoring is essential
Prialt carries a boxed warning for severe psychiatric symptoms and neurologic impairment, and a history of psychosis is a contraindication. Confusion, cognitive changes, dizziness, and gait problems can complicate treatment. Intrathecal devices also introduce procedure and infection considerations. A benefit on pain scores must be balanced against function and tolerability.
Supporting sources [1]
What the evidence does not establish
The peptide is not an over-the-counter pain remedy or a self-directed injection. A laboratory preparation is not equivalent to the licensed sterile formulation. Its mechanism illustrates how a peptide can become a useful medicine only within a defined product, route, clinical population, and monitoring framework.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic 25-amino-acid conopeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Prialt (ziconotide) prescribing information ↗Regulatory source · Checked 2026-10-27
- Intrathecal ziconotide for refractory cancer or AIDS pain: randomized trial ↗Clinical trial source · Checked 2026-10-27